Contents
On this page
- How new topics enter Good Publication Practice
- Reasons these disclosure topics are omitted
- The written agreement and its contents under GPP2
- Disclosure of the sponsor’s role in addition to funding
- Author access to data and the accountability statement
- Acknowledgement of other contributors
- Prior disclosure: abstracts, preprints and companion papers
- Unpublished studies
- Plagiarism and text recycling, including self-recycling
- Components of a complete disclosure block
- Key points
- Application to your study
- Frequently asked questions
Academy · Research Publication · Essential GPP topics
Frequently Omitted Disclosures Under Good Publication Practice (GPP)
Authors consistently declare the funding source and the medical writer. They frequently omit the written agreement, the sponsor’s role in the work, their own access to the data, the relationship between the paper and the wider publication programme, and studies that were never written up. None of these items appears on a submission form, which largely explains why they are omitted.
Good Publication Practice (GPP) covers more ground than is commonly recognised. Training that presents GPP as two requirements, disclosing the funder and naming the writer, is accurate but incomplete, and neither requirement is where disclosure most often fails. The topics most frequently omitted arise upstream of the manuscript or require uncomfortable information to be recorded. This article examines them in the order in which they tend to be omitted and compares a complete disclosure block with the version commonly submitted.
Good Publication Practice at a glance
- What it is
- Guidance on publishing research sponsored by pharmaceutical, device, diagnostics and biotechnology companies8
- Who adds new topics
- Guideline steering committees and journal editors, for example the ICMJE data sharing statement34
- Telling statistic
- 68.6% of trials in three leading journals declared data sharing; 0.6% had public participant-level data35
- This article’s focus
- The disclosures most often omitted because no submission form prompts them
- Reading time
- About 17 minutes, with 3 figures and 4 tables
Learning objectives
- Why the most-missed GPP topics are missed — none of them appears on a journal submission form
- What belongs in a written agreement, using GPP2’s own split of sponsor, author and shared responsibilities
- The difference between declaring a funding source and describing the sponsor’s role, and why editors query the second
- How to determine whether an author’s access to the data is sufficient to support the accountability statement to be signed
- Which contributors beyond the medical writer must be named, and what permission is required
- What GPP expects authors to disclose about congress abstracts, preprints and companion papers from the same dataset
Common misconceptions
- “Declaring the funder is sufficient to disclose the commercial relationship.” It does not. GPP expects the sponsor’s role in design, conduct, analysis and the decision to publish to be described, which is a different and more revealing statement.
- “The written agreement is a contractual and legal formality.” It is the document that decides, in advance, who controls the data and who may stop the publication. GPP2 sets out responsibilities on both sides precisely so that question is not answered mid-manuscript.
- “Authors have access to the data because the sponsor says they do.” Viewing a summary table does not constitute access. An accountability statement should not be signed unless it is literally true.
- “A congress abstract is not a publication, so it needs no declaration.” It is prior disclosure of the same data and GPP treats it as part of the same obligation. Editors treat undeclared prior presentation as a redundancy problem.
- “Reusing my own methods text is not plagiarism.” GPP3 added an explicit section on plagiarism, and text recycling is subject to its own rules. Reuse without attribution is a disclosure failure even when the original author is the same person.
How new topics enter Good Publication Practice
Good Publication Practice is a moving set of conventions rather than a fixed code. Each revision has added topics that earlier versions did not address, and journal editors, acting collectively through the ICMJE, have introduced requirements that sponsored publications must then meet. Figure 1 traces that sequence.
The guideline committees work by consultation. For GPP3, the steering committee drawn from 241 applicants selected 174 reviewers, of whom 94 sent comments on the second draft; the resulting guideline added sections on the principles of good publication practice, data sharing, studies that should be published, and plagiarism8. GPP 2022 widened the scope again, to enhanced content such as plain-language summaries, and placed new topics such as alliances and working with patients in its supplementary materials, with the stated aim of allowing new and emerging publication tools to be used compliantly5.
Editors move the field by a different route: they make a disclosure a condition of consideration. Writing for the ICMJE, Taichman and colleagues stated that there is an ethical obligation to share data from interventional trials because participants have put themselves at risk. After consulting on a January 2016 proposal, they concluded that the mechanisms for mandating universal sharing were not yet in place, and instead required every trial report to carry a data sharing statement, adding that editors may take these statements into account when making decisions34.
Table 1. How the topics discussed in this article entered publication practice
| Topic | Introduced through | What it asks of authors | Section below |
|---|---|---|---|
| Written agreement | GPP2, 200912 | Settle control of data, final approval and the right to delay publication before drafting | The written agreement |
| Data sharing | GPP3, 2015; ICMJE statement requirement, 20178,34 | State whether, what, when, with whom and how participant-level data will be shared | Author access to data |
| Studies that should be published | GPP3, 20158 | Plan publication of completed studies, not only those a sponsor chooses to pursue | Unpublished studies |
| Plagiarism | GPP3, 20158 | Attribute reused text, including an author’s own | Plagiarism and text recycling |
| Enhanced content and patients | GPP 20225 | Apply the same standards to plain-language summaries; recognise patient contributors | Acknowledgement of other contributors |
Why this article concentrates on omitted disclosures
Each new topic arrives as guidance long before, if ever, it arrives as a field on a submission form, and the topics that never become form fields are the ones authors most often leave out, so the remainder of this article deals with those disclosures rather than with the history of the guidelines.
Reasons these disclosure topics are omitted
There is a simple structural reason why the same GPP topics are repeatedly omitted. Journals designed their submission forms around the International Committee of Medical Journal Editors (ICMJE) Recommendations, which operate at submission 1. Consequently, the GPP requirements that overlap with the ICMJE Recommendations (authorship, acknowledgement, funding, registration and conflicts of interest) are prompted by a form and are therefore answered. The requirements that arise upstream of submission have no corresponding form. At upload, authors are not asked whether a written agreement existed before drafting, whether the authors could see the patient-level data, or what happened to the other two studies in the programme.
GPP exists largely to address this unprompted territory 8,28. Its development reflects this purpose: Battisti and colleagues report in Annals of Internal Medicine that the International Society for Medical Publication Professionals (ISMPP) invited more than 3,000 publication professionals worldwide to apply for the GPP3 steering committee or to serve as reviewers; 241 applications were reviewed, and an 18-member steering committee drawn from 7 countries was formed 8. This was a large consultation for a document whose most important clauses are unlikely ever to be checked by an editor, and its scale is significant: these are the conventions that the field agreed to observe in the absence of external enforcement.
The following sections address the topics that this consultation covered and that practice most often neglects. The upstream mechanics of who signs what, and when, are described on what GPP3 requires in practice; the present article addresses the disclosures themselves.
Where each GPP topic is prompted, and who notices if it is skipped
| Topic | Prompted at submission? | Who notices if it is missing |
|---|---|---|
| Funding source | Yes — disclosure form | The editor, immediately |
| Medical writer named | Yes — acknowledgements | The editor, who queries vague wording |
| Sponsor’s role in design, analysis and the decision to publish | Partly — often a free-text box | Reviewers, and readers drawing an inference from silence |
| Author access to data | Asserted, never verified | Nobody, until the claim is challenged |
| Written agreement before drafting | No | Only the sponsor’s own audit |
| Prior congress abstract or preprint | Sometimes | The editor, if similarity software finds it first |
| Relationship to the primary report | No | Reviewers and systematic reviewers downstream |
| Studies in the programme that were never submitted | No | Nobody — there is no external check at all |
Pubrica’s mapping of GPP topics, as set out by Graf and colleagues in BMJ (GPP2), Battisti and colleagues in Annals of Internal Medicine (GPP3) and DeTora and colleagues in Annals of Internal Medicine (GPP 2022), against the information a journal submission process actually requests. The second and third columns represent Pubrica’s interpretation, not statements from the guidelines.
The written agreement and its contents under GPP2
This is, by a considerable margin, the most frequently omitted topic, because the agreement must exist before any other step is taken and no one asks to see it.
GPP2, published by Graf and colleagues in BMJ, is the version that set out the written agreement in detail, and its structure remains the most useful framework available 12. Its written-agreement section lists 3 sponsor responsibilities, 9 author responsibilities and 8 shared responsibilities. This asymmetry is instructive: the greatest share of responsibility rests with the authors rather than the sponsor, contrary to the common assumption about how an industry publication guideline would be weighted.
In substance, the agreement must settle four questions: who controls the data and the analyses; who has final approval of the submitted wording; who may delay or stop the publication, on what grounds, and for how long 8,12; and how a disagreement on interpretation between a sponsor and an author is resolved. Each of these questions has a correct answer under GPP, and none of them can be answered neutrally once a draft is circulating and the result is known.
GPP2 was itself the product of a consultation (Graf and colleagues invited 193 people and received 116 sets of comments), and it supplied checklists for precisely this purpose 12. Where an organisation has a standard operating procedure (SOP) that mentions written agreements without specifying their content, the GPP2 breakdown provides the most direct means of making that clause enforceable. Implementation in practice is discussed in getting GPP adopted inside an organisation.
How GPP2 divided the written agreement. Source: Graf C, Battisti WP, Bridges D, Bruce-Winkler V, Conaty JM, Ellison JM, et al. Good publication practice for communicating company sponsored medical research: the GPP2 guidelines. BMJ.
Disclosure of the sponsor’s role in addition to funding
“This study was funded by X” is a funding declaration. GPP requires something more specific: a description of what the sponsor actually did. The four relevant dimensions are study design, conduct, data analysis, and the decision to publish 8,30. A sponsor may legitimately have been involved in all four; what is not legitimate is to leave the reader to infer the extent of that involvement.
The distinction matters because, in most cases, the inference a reader draws from silence is worse than the truth. A statement reading “the sponsor designed the study, performed the statistical analysis, and participated in the decision to submit; the authors had final responsibility for the content and the decision to submit” is a strong statement rather than a damaging one, because it is bounded. “Funded by X” alone leaves the full range of possibilities open, including those the author would most wish to exclude.
Rothman and colleagues, writing in JAMA on professional medical associations and industry, advanced the general form of this argument: the control of conflicts of interest depends on the specificity of what is disclosed rather than on the existence of a disclosure 15. The same logic applies at the level of a single paper.
Author access to data and the accountability statement
GPP requires that authors have access to the data and analyses that support the claims in the paper 8,12,30. In practice, this is the requirement most often satisfied in form but not in substance, because the chain of access runs through the sponsor’s statistical group and the author sees outputs rather than data.
Three levels of access are frequently conflated. Viewing the final tables, figures and listings is the weakest. The ability to request and receive specific additional analyses from the sponsor’s statisticians is stronger. Access to the analysis dataset, directly or through an independent statistician, is the strongest. GPP does not mandate the strongest level in every case, but the statement signed at submission (accountability for all aspects of the work) is more difficult to defend at the weakest level 1,2. Authors should therefore establish which level applies before writing the sentence.
Where the medical writer rather than an author is drafting, this matter should be raised explicitly with the author group, because authors frequently have not considered it and the writer is the person drafting the sentence. Where an independent check is required, that is a biostatistics question rather than a writing one.
Data access has a public counterpart in the data sharing statement. The ICMJE requirement specifies five things such a statement must say, and Table 2 sets them beside the wording of one of the committee’s own illustrative examples34.
Table 2. What an ICMJE data sharing statement must state
| Required element | Wording in the ICMJE’s second example |
|---|---|
| Whether deidentified participant data, including data dictionaries, will be shared | Yes |
| Which data will be shared | Individual participant data that underlie the results reported in this article, after deidentification |
| Which related documents will be available | Study protocol, statistical analysis plan, analytic code |
| When, and for how long | Beginning 3 months and ending 5 years following article publication |
| Access criteria: with whom, for what analyses, by what mechanism | Researchers who provide a methodologically sound proposal, to achieve the aims of the approved proposal, under a data access agreement |
Elements and example wording from Taichman et al. for the ICMJE (2017). The committee describes its examples as illustrating a range of, not all, sharing options.
Declaring is not the same as doing. Danchev and colleagues examined all 487 clinical trial reports published in JAMA, the Lancet and the New England Journal of Medicine between July 2018 and April 2020. Of these, 334 (68.6%) declared that data would be shared, but only 2 participant-level datasets were deidentified and publicly available by April 2020; of 89 articles promising repository deposit, 17 (19.1%) had deposited, and an embargo was set in 47.3% of data-sharing articles35. The same gap between a signed statement and the underlying reality is the one this section warns about for author access.
Acknowledgement of other contributors
The medical writer is usually acknowledged; other contributors frequently are not.
The statistician who performed the analysis without meeting the authorship criteria belongs in the acknowledgements, with name and employer 1,8. So does the agency that managed the publication, as distinct from the individual writer. So do language and technical editors, if their contribution was substantive. So do patient and public contributors, who are addressed explicitly in GPP 2022 rather than as a courtesy and who, like every other named individual, should give written permission, because acknowledgement implies some association with the conclusions 1,5.
Disclosure of writing support is not an admission of impropriety. Gattrell and colleagues, in BMJ Open, examined 233 randomised controlled trial reports and found that 39.1% (43 of 110) of those with declared professional medical writing support completely reported at least half of the assessed Consolidated Standards of Reporting Trials (CONSORT) items, compared with 21.1% (26 of 123) of those without such support 7. After adjustment for publication year, the odds of completely reporting at least half of the CONSORT items were 1.88 times higher with writing support (95% confidence interval 1.03 to 3.42) 7. The interval approaches 1 and the design is cross-sectional, so this finding represents an association rather than a demonstrated effect; nevertheless, it runs counter to the assumption that declared support should be minimised 6,7. See what GPP requires you to report and declare for the item-level breakdown.
Prior disclosure: abstracts, preprints and companion papers
A single trial typically generates a congress abstract, a poster, sometimes a preprint, a primary paper, one or more secondary analyses, and a plain-language summary. GPP treats these as a single disclosure obligation rather than separate events, and the characteristic failure is a congress abstract managed to a less rigorous standard than the paper it precedes, with a different author list, no declared writer, or a conclusion that the primary paper will not support 5,8.
Three things to declare about prior disclosure
- Prior presentation of the same data, declared to the journal at submission1.
- The relationship to the primary report, if this paper is a secondary or subgroup analysis, stated in the abstract and methods rather than obscured.
- Any preprint, with its DOI, because journal policies on preprints differ and an unexpected discovery by the journal is more problematic than a restriction.
Declaring a preprint does not signal that the journal version will look very different. Janda and colleagues followed the 1,399 clinical-study preprints first posted to medRxiv in September 2020: 1,077 (77.0%) had been published in a journal by September 2022, a median of 6 months after posting, and most of the 547 preprint–article pairs reporting health outcomes were concordant (Table 3)36.
Table 3. How medRxiv preprints compared with their peer-reviewed journal versions
| Feature compared | Concordant pairs | Note |
|---|---|---|
| Sample size | 462 of 535 (86.4%) | 43 of the 73 discordant pairs had a larger sample in the journal version |
| Primary end points | 534 of 547 (97.6%) | 13 pairs had a different primary end point |
| Primary end point results | 434 of 535 (81.1%) | 66 of 101 discordant pairs had estimates in the same direction and statistically consistent |
| Study interpretation | 526 of 547 (96.2%) | Including 82 of the 101 pairs with discordant results |
Source: Janda et al., JAMA Network Open, 2022. Concordance required exact numerical equivalence for sample sizes and results.
Incomplete prior-disclosure statement
“Part of this work has been presented previously.”
No venue, no date, no identifier, and no indication of whether the data or conclusions have changed.
Complete prior-disclosure statement
“Interim results were presented as a poster at [congress, month year]. A preprint of an earlier version was posted on medRxiv (doi: [identifier]); the present version adds 12-month follow-up. A secondary analysis of this trial is reported separately [reference].”
Every prior output is named with a locator, and the changes since the preprint are stated.
Illustrative statements written for this page; bracketed items are placeholders.
Complete disclosure is also the most reliable way to avoid being regarded as redundant publication. The evidence on how duplicates are detected (by reviewers, by editors and by text-similarity software) is presented in how duplicate and redundant publication is identified.
Unpublished studies
This topic has no form, no checkbox and no external check of any kind, and it is the topic that GPP3 added most explicitly. The guideline takes a position on which studies should be published, not merely on how to publish those a sponsor has chosen to pursue 8.
The rationale lies in the evidence on publication bias. Easterbrook and colleagues, in the Lancet, and Stern and Simes, in BMJ, showed that both publication and the speed of publication are associated with the direction of findings 32,33. Antes and Chalmers stated the conclusion explicitly in the Lancet: under-reporting of clinical trials is unethical 29. A literature that is missing its negative results is not a neutral literature with gaps; it is a biased one.
For a writer or publication manager, this topic takes the practical form of a question that should be asked: what other outputs has the programme produced, and what is the plan for them? If two negative studies have no publication plan, that is a GPP issue, and one that no editor is likely to raise.
Plagiarism and text recycling, including self-recycling
GPP3 added an explicit section on plagiarism, which some readers found unexpected in a guideline on sponsored research 8. Its inclusion reflects the industry publication model, in which a programme of related papers, often drafted by the same writer from the same clinical study report, creates pressure towards text reuse that an individual academic author does not face to the same extent.
Two distinctions are relevant. Reusing another person’s text without attribution is plagiarism, and Das and Panjabi explain in Perspectives in Clinical Research why medical writers are structurally exposed to it 10. Reusing one’s own previously published text is text recycling, which is governed separately (the text recycling guidance of the Committee on Publication Ethics (COPE) and Roig’s guide for the US Office of Research Integrity are the usual references) and is treated differently depending on the section, the extent of reuse, and whether the original is cited. Methods sections attract the most tolerance, although reuse there is still not unlimited.
A workable rule for a programme is to write the methods once, maintain a canonical version, cite the primary paper whenever that text is reused, and never recycle discussion or conclusion text. A similarity check before submission indicates what the editor’s software will detect.
Components of a complete disclosure block
All of the above is condensed into approximately one hundred and fifty words at the end of a manuscript. The difference between a minimal version and a complete one lies less in length than in specificity: every clause in the complete version names a party and an action, leaving nothing for the reader to infer.
The end-matter disclosure block, thin and complete
Technically present
Funding: This study was funded by Northvale Therapeutics. Acknowledgements: The authors thank all investigators and patients who participated. Editorial support was provided. Conflicts of interest: The authors declare no conflicts of interest. Data availability: Data are available on reasonable request.
Funding without role. The reader cannot tell whether the sponsor designed the study, analysed it, or decided to submit it.
“Editorial support was provided” names no person, no employer and no funder — the exact phrasing editors query.
No statement on author data access, in a paper whose analysis was run by the sponsor.
“No conflicts” alongside industry funding reads as an oversight even when it is accurate, because employees and consultants are usually involved somewhere.
Prior presentation is not declared, so similarity software may surface the congress abstract before the author does.
“Available on reasonable request” names no mechanism, no custodian and no date.
Actually complete
Funding and role of the sponsor: This study was funded by Northvale Therapeutics. The sponsor participated in study design, data collection and statistical analysis, and in the decision to submit; the authors had full editorial control of the manuscript and final responsibility for the decision to submit. Author access to data: All authors had access to the full statistical analysis plan and output, and the lead author and the independent statistician (R. Vasquez, Alder Institute) had access to the analysis dataset. Acknowledgements: Statistical analysis was performed by D. Castellanos, MSc (Northvale Therapeutics). Medical writing support, including outline and first draft under the authors’ direction, figure preparation and submission, was provided by J. Okafor, PhD (Meridian Scientific Communications), funded by Northvale Therapeutics in accordance with Good Publication Practice. A. Diallo contributed as a patient representative to the interpretation of the patient-reported outcomes. All named individuals have given written permission. Prior disclosure: These data were presented in part as a poster at the 2025 European congress (abstract 4412) and this paper reports the pre-specified primary analysis; the 24-month extension analysis is reported separately (full reference). Conflicts of interest: K.O. and S.F. report consultancy fees from Northvale Therapeutics; D.C. is an employee of Northvale Therapeutics; remaining authors declare none. Data availability: Individual participant data will be made available on request to qualified researchers via the sponsor’s data-request portal from 12 months after publication, subject to a data-sharing agreement.
The sponsor’s role is bounded across all four dimensions, and editorial control is stated separately from funding.
Data access is described at the level it actually occurred, including who saw the dataset rather than the outputs.
Writer, statistician and patient contributor are each named with employer and funder, with permission recorded.
Prior poster and companion paper are declared, with identifiers, so the relationship is on the record first.
Conflicts are itemised per author, which is what a reader can actually use.
Data availability names a route, a gatekeeper, a start date and a condition; it is a statement on which a reader could act.
The second version is longer, and none of its additions is a concession. Each addition replaces an inference the reader would otherwise have to make with a verifiable fact, and each corresponds to a GPP topic that no submission form prompts. If only one addition is made to the end matter, it should be the sponsor’s role, because the absence of this clause causes the most unrecognised damage.
Key points
Key points
The GPP topics most often omitted are those not prompted by any form: the written agreement, the sponsor’s role as distinct from its funding, the reality of author data access, prior disclosure of abstracts and preprints, the relationship between companion papers, text recycling, and studies that were never written up. GPP2’s written-agreement section (3 sponsor, 9 author and 8 shared responsibilities) remains the most usable guide to the upstream obligations. The downstream disclosures fit in a single end-matter block of about 150 words, and a complete version differs from an inadequate one in specificity rather than length.
Application to your study
Application to your study
- The written agreement should be requested by name. If no one can produce it, that absence is itself a finding. The agreement should specify who controls the data, who has final approval of wording and who may stop publication.
- The funding statement should be rewritten as a statement of the sponsor’s role. It should name the sponsor’s involvement in design, conduct, analysis and the decision to publish, and state separately who held editorial control.
- Authors should establish the level of data access they actually have (final outputs, analyses on request or the full dataset) and report it accurately.
- All non-author contributors should be listed before the acknowledgements are drafted. These may include the writer, statistician, agency, language editor and patient contributors. Written permission should be obtained for each name.
- All prior outputs from the same data should be inventoried. Abstracts, posters, preprints and companion papers should be declared to the editor, and the primary report cross-referenced in the abstract.
- A single canonical methods text should be maintained per programme, with the primary paper cited whenever it is reused. Discussion and conclusions should never be recycled.
- A similarity check should be run before submission rather than left to the editor. This allows authors to identify in advance what the journal’s software will detect.
- Authors should ask what other outputs the programme has produced and what publication plan exists. A completed study with no publication plan is a GPP problem that no journal is likely to raise.
Frequently asked questions
The written agreement that should exist before drafting begins. It is omitted because it has no external check: no journal requests it, and no editor can see whether one existed. GPP2, from Graf and colleagues in BMJ, remains the most detailed treatment: its written-agreement section sets out 3 sponsor responsibilities, 9 author responsibilities and 8 shared responsibilities. In substance, the agreement must settle who controls the data, who has final approval of the wording, who may delay or stop the publication and on what grounds, and how a disagreement over interpretation is resolved. None of these questions can be answered neutrally once results are known.
No. GPP expects the sponsor’s role to be described, not merely its existence disclosed. The statement should specify whether the sponsor was involved in study design, data collection or conduct, statistical analysis, and the decision to submit, and should state separately who held editorial control of the manuscript. The rationale is practical: a bounded statement is less damaging than silence, because a reader confronted with “funded by X” alone must consider the full range of possible sponsor involvement, including the forms the author would most wish to exclude. Rothman and colleagues made the general case in JAMA that specificity, rather than disclosure as such, is what manages conflicts of interest.
There are three practical levels of access, and GPP does not treat them as equivalent. The weakest is viewing the final tables, figures and listings. The intermediate level is the ability to request and receive specific further analyses from the sponsor’s statisticians. The strongest is access to the analysis dataset, directly or through an independent statistician. GPP requires access to the data and analyses supporting the claims, and the accountability statement signed at submission is easier to defend at higher levels of access. Authors should establish which level applies before drafting the sentence that asserts it.
Yes: to the journal at submission, and usually in the paper itself. GPP treats congress abstracts, posters, preprints, the primary paper, secondary analyses and plain-language summaries as a single disclosure obligation rather than separate events. The common failure is an abstract developed to a less rigorous standard than the paper it precedes, with a different author list, no declared writing support, or a conclusion that the full analysis will not support. Declaring prior presentation also protects the authors, because text-similarity software run by the publisher will identify the abstract whether or not it was disclosed.
It is text recycling rather than plagiarism, and it is governed separately, but it is not unrestricted. COPE’s text recycling guidance and Roig’s guide for the US Office of Research Integrity are the standard references; GPP3 added an explicit plagiarism section partly because programme-based publishing creates pressure towards reuse. Tolerance is highest for methods, where the underlying procedure has genuinely not changed, and lowest for discussion and conclusions. A workable rule for a programme is to maintain one canonical methods text, cite the primary paper whenever it is reused, and never recycle interpretation.
Not in a way that the data support. Gattrell and colleagues, in BMJ Open, examined 233 randomised controlled trial reports and found that 39.1% of those with declared professional medical writing support completely reported at least half of the assessed CONSORT items, compared with 21.1% of those without, an odds ratio of 1.88 after adjustment for publication year (95% confidence interval 1.03 to 3.42). The interval approaches 1 and the study is cross-sectional, so the finding should be treated as an association rather than a proven effect. It does not, however, support the view that declared support indicates poorer reporting.
All named parties. Acknowledgement may be read as implying some endorsement of the conclusions, so written permission should be obtained from each named individual or organisation: the medical writer, the statistician, the language editor, the agency, and any patient or public contributor. Permission is easily collected at the time and difficult to collect retrospectively, so it should be gathered while the acknowledgements are drafted rather than at submission. For patient contributors in particular, authors should confirm the name and description they wish to be used; GPP 2022 treats their contribution as a contribution rather than a courtesy.
GPP3 added an explicit section on which studies should be published, and it is the only GPP topic with no external enforcement: no editor can see a paper that was never submitted. The underlying evidence is the publication bias literature: Easterbrook and colleagues in the Lancet and Stern and Simes in BMJ both showed that whether and how quickly research is published is associated with the direction of its findings, and Antes and Chalmers argued in the Lancet that under-reporting of trials is unethical. In practice, the question to ask of any programme is what other studies were completed and what plan exists for them.
References
- International Committee of Medical Journal Editors. Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals. ICMJE. 2026. read 9 October 2026. icmje.org
- International Committee of Medical Journal Editors. The New ICMJE Recommendations (August 2013). ICMJE. 2013. read 9 October 2026. icmje.org
- Committee on Publication Ethics. Core Practices. COPE. read 9 October 2026. equator-network.org
- International Society for Medical Publication Professionals. GPP 2022: Good Publication Practice guidelines for company-sponsored biomedical research published in Annals of Internal Medicine (press release). ISMPP. 2022. read 9 October 2026. ismpp.org
- DeTora LM, Toroser D, Sykes A, Vanderlinden C, Plunkett FJ, Lane T, Hanekamp E, Dormer L, DiBiasi F, Bridges D, Baltzer L, Citrome L. Good Publication Practice (GPP) Guidelines for Company-Sponsored Biomedical Research: 2022 Update. Annals of Internal Medicine. 2022;175(9):1298-1304. doi:10.7326/M22-1460 read 9 October 2026. doi.org/10.7326/M22-1460
- Mills I, Sheard C, Hays M, Douglas K, Winchester CC, Gattrell WT. Professional medical writing support and the reporting quality of randomized controlled trial abstracts among high-impact general medical journals. F1000Research. 2017;6:1489. doi:10.12688/f1000research.12268.2 read 9 October 2026. doi.org/10.12688/f1000research.12268.2
- Gattrell WT, Hopewell S, Young K, Farrow P, White R, Wager E, Winchester CC. Professional medical writing support and the quality of randomised controlled trial reporting: a cross-sectional study. BMJ Open. 2016;6(2):e010329. doi:10.1136/bmjopen-2015-010329 read 9 October 2026. doi.org/10.1136/bmjopen-2015-010329
- Battisti WP, Wager E, Baltzer L, Bridges D, Cairns A, Carswell CI, Citrome L, Gurr JA, Mooney LA, Moore BJ, Pena T, Sanes-Miller CH, Veitch K, Woolley KL, Yarker YE. Good Publication Practice for Communicating Company-Sponsored Medical Research: GPP3. Annals of Internal Medicine. 2015;163(6):461-464. doi:10.7326/M15-0288 read 9 October 2026. doi.org/10.7326/M15-0288
- Wislar JS, Flanagin A, Fontanarosa PB, et al. Honorary and ghost authorship in high impact biomedical journals: a cross sectional survey. BMJ. 2011;343:d6128. doi:10.1136/bmj.d6128 read 9 October 2026. doi.org/10.1136/bmj.d6128
- Das N, Panjabi M. Plagiarism: why is it such a big issue for medical writers? Perspectives in Clinical Research. 2011;2(2):67-71. doi:10.4103/2229-3485.80370 read 9 October 2026. doi.org/10.4103/2229-3485.80370
- Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. Annals of Internal Medicine. 2010;152:726-732. read 9 October 2026. care-statement.org
- Graf C, Battisti WP, Bridges D, Bruce-Winkler V, Conaty JM, Ellison JM, Field EA, Gurr JA, Marx M-E, Patel M, Sanes-Miller C, Yarker YE. Good publication practice for communicating company sponsored medical research: the GPP2 guidelines. BMJ. 2009;339:b4330. doi:10.1136/bmj.b4330 read 9 October 2026. doi.org/10.1136/bmj.b4330
- Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Medicine. 2009;6:e1000097. read 9 October 2026. care-statement.org
- Woloshin S, Schwartz LM, Casella SL, Kennedy AT, Larson RJ. Press releases by academic medical centers: not so academic? Annals of Internal Medicine. 2009;150:613-618. read 9 October 2026. archive.emwa.org
- Rothman DJ, McDonald WJ, Berkowitz CD, Chimonas SC, DeAngelis CD, Hale RW, et al. Professional medical associations and their relationships with industry: a proposal for controlling conflict of interest. JAMA. 2009;301(13):1367-1372. read 9 October 2026. equator-network.org
- Gotzsche PC, Kassirer JP, Woolley KL, Wager E, Jacobs A, Gertel A, et al. What should be done to tackle ghostwriting in the medical literature? PLoS Medicine. 2009;6(2):e1000023. read 9 October 2026. archive.emwa.org
- Ross JS, Hill KP, Egilman DS, Krumholz HM. Guest authorship and ghostwriting in publications related to rofecoxib: a case study of industry documents from rofecoxib litigation. JAMA. 2008;299:1800-1812. read 9 October 2026. archive.emwa.org
- Angell M. Industry-sponsored clinical research: a broken system. JAMA. 2008;300:1069-1071. read 9 October 2026. archive.emwa.org
- Titus SL, Wells JA, Rhoades LJ. Repairing research integrity. Nature. 2008;453:980-982. read 9 October 2026. archive.emwa.org
- Hill KP, Ross JS, Egilman DS, Krumholz HM. The ADVANTAGE seeding trial: a review of internal documents. Annals of Internal Medicine. 2008;149:251-258. read 9 October 2026. archive.emwa.org
- Norris R, Bowman A, Fagan JM, Gallagher ER, Geraci AB, Gertel A, et al. International Society for Medical Publication Professionals (ISMPP) position statement. Current Medical Research and Opinion. 2007;23:1837-1840. read 9 October 2026. archive.emwa.org
- von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ. 2007;335:806-808. read 9 October 2026. care-statement.org
- Jacobs A, Wager E. EMWA guidelines on the role of medical writers in developing peer-reviewed publications. Current Medical Research and Opinion. 2005;21:317-321. read 9 October 2026. archive.emwa.org
- von Elm E, Poglia G, Walder B, Tramer MR. Different patterns of duplicate publication: an analysis of articles used in systematic reviews. JAMA. 2004;291(8):974-980. doi:10.1001/jama.291.8.974 read 9 October 2026. doi.org/10.1001/jama.291.8.974
- Steinbrook R. Public registration of clinical trials. New England Journal of Medicine. 2004;351:315-317. doi:10.1056/NEJMp048191 read 9 October 2026. doi.org/10.1056/NEJMp048191
- Hamilton CW, Royer MG; AMWA 2002 Task Force on the Contributions of Medical Writers to Scientific Publications. AMWA position statement on the contributions of medical writers to scientific publications. AMWA Journal. 2003;18:13-16. read 9 October 2026. archive.emwa.org
- Wager E, Field EA, Grossman L. Good publication practice for pharmaceutical companies. Current Medical Research and Opinion. 2003;19(3):149-154. doi:10.1185/030079903125001767 read 9 October 2026. doi.org/10.1185/030079903125001767
- Wager E, Field EA, Grossman L. Good publication practice for pharmaceutical companies: why we need another set of guidelines. Current Medical Research and Opinion. 2003;19(3):147-148. read 9 October 2026. ismpp.org
- Antes G, Chalmers I. Under-reporting of clinical trials is unethical. Lancet. 2003;361:978-979. read 9 October 2026. ismpp.org
- Davidoff F, DeAngelis CD, Drazen JM, Hoey J, Hojgaard L, Horton R, et al. Sponsorship, authorship, and accountability. Annals of Internal Medicine. 2001;135:463-466. read 9 October 2026. ismpp.org
- Rennie D, Flanagin A, Yank V. The contributions of authors. JAMA. 2000;284:89-91. read 9 October 2026. ismpp.org
- Stern JM, Simes RJ. Publication bias: evidence of delayed publication in a cohort study of clinical research papers. BMJ. 1997;315:640-645. read 9 October 2026. ismpp.org
- Easterbrook PJ, Berlin JA, Gopalan R, Matthews DR. Publication bias in clinical research. Lancet. 1991;337(8746):867-872. read 13 November 2026. View via DOI
- Taichman DB, Sahni P, Pinborg A, et al. Data sharing statements for clinical trials: a requirement of the International Committee of Medical Journal Editors. Ethiopian Journal of Health Sciences. 2017;27(4):315-318. PMCID: PMC5615020 read 13 November 2026. pubmed.ncbi.nlm.nih.gov/29217933
- Danchev V, Min Y, Borghi J, Baiocchi M, Ioannidis JPA. Evaluation of data sharing after implementation of the International Committee of Medical Journal Editors data sharing statement requirement. JAMA Network Open. 2021;4(1):e2033972. doi:10.1001/jamanetworkopen.2020.33972 read 13 November 2026. doi.org/10.1001/jamanetworkopen.2020.33972
- Janda G, Khetpal V, Shi X, Ross JS, Wallach JD. Comparison of clinical study results reported in medRxiv preprints vs peer-reviewed journal articles. JAMA Network Open. 2022;5(12):e2245847. doi:10.1001/jamanetworkopen.2022.45847 read 13 November 2026. doi.org/10.1001/jamanetworkopen.2022.45847
Every source above is a peer-reviewed article, a publisher’s record of one, or a standard issued by the body that owns it. Each carries the date it was last read. Where a standard moves, this article is revised rather than left up with a note.
How to cite this article
Pick your referencing style and copy it. Your university or target journal may vary the punctuation — check its guide if it has one.
Pubrica Academy. (2026, October 9). Frequently Omitted Disclosures Under Good Publication Practice (GPP). Pubrica. https://pubrica.com/academy/concepts-definitions/essential-topics-that-drive-science-forward-of-gpp/
Pubrica Academy. “Frequently Omitted Disclosures Under Good Publication Practice (GPP).” Pubrica, 9 Oct. 2026, pubrica.com/academy/concepts-definitions/essential-topics-that-drive-science-forward-of-gpp/.
Pubrica Academy (2026) Frequently Omitted Disclosures Under Good Publication Practice (GPP). Pubrica. Available at: https://pubrica.com/academy/concepts-definitions/essential-topics-that-drive-science-forward-of-gpp/ (Accessed: 15 October 2026).
Pubrica Academy. “Frequently Omitted Disclosures Under Good Publication Practice (GPP).” Pubrica. October 9, 2026. https://pubrica.com/academy/concepts-definitions/essential-topics-that-drive-science-forward-of-gpp/
Pubrica Academy, ‘Frequently Omitted Disclosures Under Good Publication Practice (GPP)’ (Pubrica, 9 October 2026) <https://pubrica.com/academy/concepts-definitions/essential-topics-that-drive-science-forward-of-gpp/> accessed 15 October 2026.
Pubrica Academy. Frequently Omitted Disclosures Under Good Publication Practice (GPP). [Internet]. Pubrica; 2026 Oct 9 [cited 2026 Oct 15]. Available from: https://pubrica.com/academy/concepts-definitions/essential-topics-that-drive-science-forward-of-gpp/
Pubrica Academy, “Frequently Omitted Disclosures Under Good Publication Practice (GPP),” Pubrica, Oct. 9, 2026. [Online]. Available: https://pubrica.com/academy/concepts-definitions/essential-topics-that-drive-science-forward-of-gpp/
@misc{essential_topics_that_drive_science_fo_2026,
author = {{Pubrica Academy}},
title = {Frequently Omitted Disclosures Under Good Publication Practice (GPP)},
howpublished = {Pubrica},
year = {2026},
month = {oct},
url = {https://pubrica.com/academy/concepts-definitions/essential-topics-that-drive-science-forward-of-gpp/},
note = {Accessed: <span data-cite-acc="iso">2026-10-15</span>}
}This article is written to be learned from. Cite it if you are referring to what it says; if you are using the evidence behind it, cite the sources listed above instead.
GPP disclosure block worksheet
This checklist should be completed before the end matter is drafted. Each line is a GPP topic that no submission form will prompt. Where a line cannot be completed, the item should be raised with the author group or the sponsor rather than softened with vague wording.
GPP DISCLOSURE WORKSHEET Manuscript: ______________________ Programme / study: ______________________ 1. WRITTEN AGREEMENT Exists? [ ] yes [ ] no [ ] cannot establish Dated: __________ Controls the data: ______________________ Final say on submitted wording: ______________________ May delay or stop publication, and on what grounds: ______________________ Disagreement on interpretation resolved by: ______________________ 2. SPONSOR'S ROLE (tick what applies; this becomes the role statement) [ ] study design [ ] data collection / conduct [ ] statistical analysis [ ] interpretation [ ] decision to submit Editorial control of the manuscript held by: ______________________ 3. AUTHOR ACCESS TO DATA (choose the level that is actually true) [ ] final tables, figures and listings only [ ] further analyses available on request from the sponsor's statisticians [ ] access to the analysis dataset, by: ______________________ [ ] independent statistician involved: ______________________ 4. NON-AUTHOR CONTRIBUTORS (name, employer, what they did, who funded it, written permission obtained) Medical writer ....... ______________________________________ perm [ ] Statistician ......... ______________________________________ perm [ ] Agency ............... ______________________________________ perm [ ] Language/tech editor . ______________________________________ perm [ ] Patient contributor .. ______________________________________ perm [ ] Other ................ ______________________________________ perm [ ] 5. PRIOR AND RELATED DISCLOSURE (list every output from these data) Congress abstracts / posters: ______________________________________ Preprint + DOI: ______________________________________ Primary report (if this is secondary): ______________________________ Companion / secondary papers: ________________________________________ [ ] All declared to the editor at submission [ ] Relationship to the primary report stated in the abstract and methods 6. TEXT REUSE [ ] Methods text drawn from a canonical version; primary paper cited [ ] No reused discussion or conclusion text [ ] Similarity check run before submission; report reviewed 7. DATA AVAILABILITY Route: ______________________ Custodian: ______________________ Available from: __________ Conditions: ______________________ 8. PROGRAMME-LEVEL QUESTION (ask it, and record the answer) Other completed studies in this programme: ______________________ Publication plan for each: ______________________ [ ] Any completed study with no plan has been escalated
Pubrica AcademyWritten and maintained by Pubrica’s subject matter experts. Articles are revised when the underlying standards change, and each article states the date on which it was last reviewed.
How Pubrica can help
Pubrica drafts the funding, sponsor-role, data-access, acknowledgement and data-availability statements as a single block rather than as separate additions, and raises early the questions that the end matter will eventually have to answer: who controls the data, what other outputs the programme has produced and who else should be named. Where an answer is problematic, Pubrica advises on what an editor is likely to infer from its omission.